🇺🇸 FDA
Patent

US 9139529

Substituted quinoxalines as sodium channel modulators

granted A61KA61K31/47A61K31/4709

Quick answer

US patent 9139529 (Substituted quinoxalines as sodium channel modulators) held by Vertex Pharmaceuticals Incorporated expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K31/47, A61K31/4709, A61K31/498, A61P